New resource available view now
New resource available view now
Recent Post
Related Posts
Patent-pending multi-agent architecture targets fragmented biomedical data and expands toward imaging, omics, and broader health-data applications ahead of planned AAIC 2026 demonstration in London
Psilocybin, a psychedelic compound in “magic mushrooms,” has shown potential in treating refractory depression, addiction, and terminal cancer-related anxiety. Although early studies show promising results, further research is needed to
Company continuing limited over-enrollment activities to account for attrition and support robust modified intent-to-treat, end-of-treatment, and exploratory analyses
POTOMAC, Maryland – June 9, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company developing therapeutics for Alzheimer’s disease, today announced that Ascendiant Capital Markets
Approximately 80% of target participants have completed trial participation, strengthening momentum toward database lock and topline analysis